← Back to Search

Other

Orforglipron for Obesity (ATTAIN-1 Trial)

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 72
Awards & highlights

Summary

This trial will explore if a new pill can help adults with obesity or overweight and related health issues.

Who is the study for?
This trial is for adults with obesity or overweight who also have weight-related health issues like high blood pressure, sleep apnea, heart disease, or high cholesterol. Participants should have a BMI of 30 or higher and a history of unsuccessful dieting to lose weight.Check my eligibility
What is being tested?
The study is testing Orforglipron, an oral medication taken once daily, against a placebo to see if it's effective and safe in helping people with obesity or overweight reduce their body weight.See study design
What are the potential side effects?
While the specific side effects are not listed here, common side effects for weight loss drugs can include digestive issues such as nausea and constipation, headaches, dizziness, dry mouth, and potential changes in mood.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 72
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 72 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Percent Change from Baseline in Body Weight
Secondary outcome measures
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Mean Change from Baseline in Fasting Glucose
Mean Change from Baseline in Hemoglobin A1c (HbA1c) %
+6 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Orforglipron Dose 3Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group II: Orforglipron Dose 2Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group III: Orforglipron Dose 1Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will be given placebo.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
GLP-1 receptor agonists, such as those similar to Orforglipron, mimic the incretin hormone GLP-1, which is naturally released after eating. They enhance insulin secretion, reduce glucagon levels, slow gastric emptying, and increase feelings of fullness. These actions collectively help reduce food intake and promote weight loss, making them effective for managing obesity by addressing both metabolic and appetite-related factors.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,215,110 Total Patients Enrolled
57 Trials studying Obesity
48,825 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
413,476 Total Patients Enrolled
40 Trials studying Obesity
28,544 Patients Enrolled for Obesity

Media Library

Orforglipron (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05869903 — Phase 3
Obesity Research Study Groups: Orforglipron Dose 1, Orforglipron Dose 2, Orforglipron Dose 3, Placebo
Obesity Clinical Trial 2023: Orforglipron Highlights & Side Effects. Trial Name: NCT05869903 — Phase 3
Orforglipron (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05869903 — Phase 3
Obesity Patient Testimony for trial: Trial Name: NCT05869903 — Phase 3
~1444 spots leftby Sep 2025